ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,08068
0,00%
Bitcoin
103.375,19
-0,72%
Brent Oil
80,005
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Acadia Pharmaceuticals Inc (ACAD)

  7. Acadia Pharmaceuticals Inc (ACAD) Notícias

ACAD

Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACAD
DataHoraFonteTítuloCódigoCompanhia
17/01/202518:05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
14/01/202511:05Business WireAcadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
30/12/202419:37PR Newswire (US)Acadia Pharmaceuticals Set to Join S&P SmallCap 600NASDAQ:ACADAcadia Pharmaceuticals Inc
19/12/202418:05Business WireAcadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025NASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202418:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202418:05Business WireAcadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
10/12/202420:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
10/12/202420:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
09/12/202411:00Business WireAcadia Pharmaceuticals Appoints Thomas Garner Chief Commercial OfficerNASDAQ:ACADAcadia Pharmaceuticals Inc
26/11/202418:05Business WireAcadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711NASDAQ:ACADAcadia Pharmaceuticals Inc
21/11/202418:05Business WireAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNASDAQ:ACADAcadia Pharmaceuticals Inc
14/11/202408:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
06/11/202418:05Business WireAcadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
05/11/202418:05Business WireAcadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
17/10/202419:41Business WireAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202417:07Business WireAcadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202417:07Business WireAcadia Pharmaceuticals annonce l’approbation de DAYBUE™ (trofinétide) par Santé Canada pour le traitement du syndrome de RettNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202418:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202417:15Business WireCatherine Owen Adams Succeeds Steve Davis as CEO of Acadia PharmaceuticalsNASDAQ:ACADAcadia Pharmaceuticals Inc
20/08/202417:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
14/08/202409:04Business WireRyan Reynolds Announces More to Parkinson’s® CampaignNASDAQ:ACADAcadia Pharmaceuticals Inc
07/08/202417:30Business WireAcadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
06/08/202417:05Business WireAcadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
24/07/202417:05Business WireAcadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
18/07/202410:04Business WireClinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in MedNASDAQ:ACADAcadia Pharmaceuticals Inc
18/06/202410:04Business WireAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific MeetingNASDAQ:ACADAcadia Pharmaceuticals Inc
15/05/202410:05Business WireAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
08/05/202417:05Business WireAcadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
29/04/202417:16Business WireAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipNASDAQ:ACADAcadia Pharmaceuticals Inc
24/04/202417:05Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACAD

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PMAM3
PARANAPANEMA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMOB3
Automob Participacoes ON
BOV
BRAV3
Brava Energia ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
AMER3
Americanas ON
BOV
HBRE3
HBR Realty Empreendiment... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados